Centessa Pharmaceuticals Announces Additions to Senior Leadership Team
03 Outubro 2023 - 9:00AM
Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage
pharmaceutical company that aims to discover and develop medicines
that are transformational for patients, today announced the
appointment of April Dovholuk and Ellie Im, MD to Centessa’s
executive team as Senior Vice President of Development Operations
and Senior Vice President of Clinical Development, Oncology,
respectively. In these newly created roles, Ms. Dovholuk will lead
both Centessa’s global Clinical Trials and Development Operations
teams, and Dr. Im will manage clinical development of the Company’s
Oncology programs based on the LockBody® technology platform.
“We are thrilled to welcome two new accomplished and experienced
leaders to the Centessa executive team at this exciting juncture
when we have SerpinPC in global registrational studies for the
treatment of hemophilia B; LB101, our first LockBody candidate in a
Phase 1/2a first-in-human trial for the treatment of solid tumors;
and, ORX750, our development candidate for narcolepsy and other
sleep/wake disorders in IND-enabling studies,” said Saurabh Saha MD
PhD, Chief Executive Officer of Centessa. “April has an impressive
track record in global clinical trial strategy and execution across
all stages of drug development. Ellie is a physician scientist
and recognized leader in oncology clinical development and medical
affairs. April and Ellie further strengthen the clinical and
operational teams across our company and position us well as we
look to advance current and future clinical programs across our
portfolio.”
Ms. Dovholuk is an experienced global operational leader. Prior
to joining Centessa, Ms. Dovholuk was Senior Vice President,
Clinical Development Operations at Replimune where she led teams in
clinical operations, data management, process improvement and CRO
management. Ms. Dovholuk also spent 10 years with Takeda Oncology
in various clinical operations roles supporting development
operations and managing multiple assets throughout the drug
development process. Ms. Dovholuk holds a BS from Cornell
University.
Dr. Im is an experienced drug developer and leader. She most
recently served as Senior Vice President, Clinical Development and
Operations at Mersana Therapeutics Inc. Previously, Dr. Im was
Clinical Development Lead and Senior Medical Director at Tesaro
Inc., an oncology-focused company that was later acquired by
GlaxoSmithKline plc. She also served as Medical Director for Merck
& Co, Oncology Clinical Development where she was medical lead
for the KEYNOTE-010 and –021 studies. Dr. Im is a medical
oncologist and holds an MD from Catholic University College of
Medicine, South Korea. She is Board certified in Internal Medicine
and Medical Oncology and a member of the American Society of
Clinical Oncology and Hematology.
About Centessa
Pharmaceuticals Centessa Pharmaceuticals plc is
a clinical-stage pharmaceutical company that aims to discover and
develop medicines that are transformational for patients. Our
programs span discovery-stage to late-stage development and cover a
range of high-value indications. We operate with the conviction
that each one of our programs has the potential to change the
current treatment paradigm and establish a new standard of care.
For more information, visit http://www.centessa.com/, which does
not form part of this release.
Forward Looking StatementsThis press release
contains forward-looking statements. These statements may be
identified by words such as “may,” “might,” “will,” “could,”
“would,” “should,” “expect,” “intend,” “plan,” “objective,”
“anticipate,” “believe,” “estimate,” “predict,” “potential,”
“continue,” “ongoing,” “aim,” “seek,” and variations of these words
or similar expressions that are intended to identify
forward-looking statements. Any such statements in this press
release that are not statements of historical fact may be deemed to
be forward-looking statements, including statements related to the
Company’s ability to deliver impactful medicines to patients; the
ability of our management team and board to drive execution of the
Company’s portfolio of programs; our asset-centric business model
and the intended advantages and benefits thereof; research and
clinical development plans and the timing thereof; the scope,
progress, results and costs of developing our product candidates or
any other future product candidates; our current expectations
concerning, amongst other things, the development and therapeutic
potential and benefits of our product candidates, including
SerpinPC, LB101, LB206, ORX750 and other OX2R agonists; strategy;
regulatory matters, including the timing and likelihood of
initiating clinical trials, reporting clinical trial results,
submitting an IND and the success of obtaining authorizations to
initiate or continue clinical trials or market any products; and
the market size and opportunity for our product candidates. Any
forward-looking statements in this press release are based on our
current expectations, estimates and projections only as of the date
of this release and are subject to a number of risks and
uncertainties that could cause actual results to differ materially
and adversely from those set forth in or implied by such
forward-looking statements. These risks and uncertainties include,
but are not limited to, risks related to the safety and
tolerability profile of our product candidates; our ability to
protect and maintain our intellectual property position; business
(including commercial viability), regulatory, economic and
competitive risks, uncertainties, contingencies and assumptions
about the Company; risks inherent in developing product candidates
and technologies; future results from our ongoing and planned
clinical trials; our ability to obtain adequate financing,
including through our financing facility with Oberland, to fund our
planned clinical trials and other expenses; trends in the industry;
the legal and regulatory framework for the industry, including the
receipt and maintenance of clearances to conduct or continue
clinical testing; future expenditures risks related to our
asset-centric corporate model; the risk that any one or more of our
product candidates will not be successfully developed and/or
commercialized; the risk that the results of non-clinical studies
or clinical studies will not be predictive of future results in
connection with future studies; and geo-political risks such as the
Russia-Ukraine war. These and other risks concerning our programs
and operations are described in additional detail in our Annual
Report on Form 10-K, Quarterly Reports on Form 10-Q, and our other
reports, which are on file with the U.S. Securities and Exchange
Commission (SEC). We explicitly disclaim any obligation to update
any forward-looking statements except to the extent required by
law.
Contact:Kristen K. Sheppard, Esq.SVP of
Investor Relationsinvestors@centessa.com
Centessa Pharmaceuticals (NASDAQ:CNTA)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Centessa Pharmaceuticals (NASDAQ:CNTA)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024